TP53 and intrahepatic cholangiocarcinoma: A total of 109 (42.6%) patients had AML with recurrent genetic abnormalities as defined by the 2022 ICC classification, whereas 84 (32.8%) and 19 (7.4%) were classified as having AML with MR mutations and AML with mutated TP53, respectively.